To date, results from the phase III clinical trials showed that both the Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) mRNA vaccines achieved 9095% efficacy in protecting against COVID-19 (refs 1,2 ), while the AdV vaccines (ChAdOx1 nCoV-19) and Gam-COVID-vac (Sputnik V) showed protection at a slightly lower efficacy (average 70% and 91%, respectively) 3,4
Astaxanthin ameliorated parvalbumin-positive neuron deficits and Alzheimers disease-related pathological progression in the hippocampus of AppNL-G-F/NL-G-F mice
For translation, multi-parameter panels that combine CSF/serum lipid-peroxidation markers (e.g., F 2 -isoprostanes, HNE adducts), protein injury footprints (nitrotyrosine, carbonyls) and compartment-targeted reporters in experimental models (matrix/ER/nuclear H 2 O 2 sensors, peroxiredoxin redox state) and that are aligned to cognitive or motor end-points allow mechanism-anchored evaluation of interventions (Murphy et al
Lo YH, Yang SF, Cheng CC, Hsu KC, Chen YS, Chen YY, et al
Valvi D, Mendez MA, Martinez D, Grimalt JO, Torrent M, Sunyer J, et al
J.NucciC.et al (2023)
